The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

These real-world results support the effectiveness of maternal RSV vaccination and could influence policy decisions in other ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Vaccine advisers to the FDA decided Thursday that only strains of the JN.1 variant should be targeted by updated versions of covid vaccines that will be available next fall and winter. Separately, ...

The transaction is expected to close in the third quarter subject to fulfillment of customary closing conditions, including receipt of required regulatory approvals and 3SBio shar ...

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple myeloma drug into pivotal trials. The candidate in question, an oral p300 ...